Overview

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered by Oral Inhalation) with Moxifloxacin and Placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Treatments:
Dihydroergotamine
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination